The prevalences of chronic kidney disease, the proportion of insulin treatment, and the distributions of concomitant medications (other antidiabetic oral medications, antihypertensives, and lipid-lowering agents) revealed significant differences between the two groups. The gene discussed is INS; the disease is chronic kidney disease.